Contenido exclusivo para el profesional de la salud

Psoriasis

La psoriasis en placas moderada a grave es una enfermedad sistémica, inmunomediada crónica, dolorosa y discapacitante. Su manifestación clínica más habitual es la aparición de lesiones cutáneas elevadas e inflamadas de tamaño variable, enrojecidas y recubiertas de escamas blanquecinas de grosor variable.

Tipos de PSO

1. Rol del TNF-α

Múltiples enfermedades inflamatorias inmuno-mediadas comparten una vía inflamatoria común: el TNF-α.1, 2

2. ¿Qué es la psoriasis? 

La psoriasis en placas es una enfermedad inflamatoria, crónica y sistématica, que afecta más allá de la piel. 4

3. Síntomas de psoriasis en placas

 

4. Psoriasis niños

La psoriasis afecta la autoestima, la vida social y la etapa escolar.6-9

5. Artritis Psoriásica

La artritis psoriásica afecta a 3 de cada 10 pacientes con psoriasis.5,12

6. Guías Británicas

Adalimumab, ustekinumab o secukinumab, el tratamiento recomendado de 1a línea recomendado para pacientes de Pso y APs.14

7. Terapia biológica

Para conocer más de la terapia biológica dé click en el siguiente enlace:

CONOZCA MÁS

8. Psoriasis Ungueal

Cinco cosas que debe saber sobre la psoriasis ungueal.

  1. Gottlieb A, Kerman N. Gordon B. Feldman SR et al. Guidelines of care for the management of psoriasis and prioritic arthritis: Section 2 Pacriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008,53.851-64
  2. Tracey D. Klareskog, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacology & Therapeutics 2008, 117.244 279
  3. MeasePl. Gladman DD, Ritchin CT et al. Adalimumas for the Treatment of Patients with Moderately to Severely Active Psoriatic Arthritis Arthritis & Rheumatium 2005,52(10):3279-3289
  4. Global report on psoriasis. World Health Organization 2016
  5. Raychaudhuri SP, Gross). A Comparative study of Pediatric Onset Psoriasis with Adult Onset Psoriasis. Pediatric Dermatology 2000;17(3): 174-178
  6. Rogers M. Childhood psoriasis. Current Opinion in Pediatrics 2002 14:404-409
  7. Psoriasis. Report by the Secretariat. World Health Organization. 5 April 2013
  8. Foliadou Lazardou E, loannides D. Management of psoriasis in adolescence. Adolescent Hear Medicine and Therapeutics 2014.525-34
  9. Ayala F. Clinical presentation of psoriasis Reumatismo 2007.59(1):40-45
  10. Lin VW Tough-Skinned Kids: Identifying Psychosocial Effects of Psoriasis and helping Pediatric Patients and Families Cope Journal of Pediatric Nursing 2012:27:563-572
  11. National Psoriasis Fundation Comorbidities Associated with Psoriatic Disease Consultado el 30.10.15 en: http://www.prisis.org/aboutpsariasis/related conditions
  12. Mente A Karman Nl. Elmets CA et al. Guidelines of care for the management of psoriasis and picriatic arthritis. J Am Acad Dermatol 2011;65-137-74
  13. Smith CH. Jabbar-Lopez ZK. Yiu ZZ et al. British Association of Dermatologists guidelines for biologic therapy for pieriasis 2017. British Journal of Dermatology 2017,177.625-636
  14. Elewsky BE et al. Adalimumab for Nail Psoriasis: Efficacy and Safety from the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial. Presented at the 5th Congress of the Psoriasis International Network (Psoriasis 2016) • Paris, France • July 7 –9, 2016. 
  15. Radtke MA et al. Nail psoriasis – a treatment challenge. J Dtsch Dermatol Ges. 2013 Mar;11(3):203-19. 
  16. 17. Radtke MA et al. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011 Jul;2:1-6. 
  17. Jiaravuthisan MM et al. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27. 
  18. Samman PD, Fenton DA. Samman's The Nails in Disease. St Thomas's Hospital, St John's Institute of Dermatology. Fifth Edition. 1995.
  19.  Reich K. Approach to managing patients with nail psoriasis. JEADV. 2009;23(Suppl. 1), 15–21. 
  20.  de Berker D. Management of Psoriatic Nail Disease. Semin Cutan Med Surg. 2009;28:39 43. 
  21. Klaassen KMG et al. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013) 169, pp314-9.
  22.  Schons KRR et al. Nail psoriasis: a review of the literatura. An Bras
  23. Dermatol. 2014;89(2):312-7. 24. Raposo I, Torres T. Nail psoriasis as a predictor of the Development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106(6):452-7. 
  24. Cassell SE et al. The Modified Nail Psoriasis Severity Index: Validation of an Instrument to Assess Psoriatic Nail Involvement in Patients with Psoriatic Arthritis. J Rheumatol 2007;34:123-9. 
  25. Crowley JJ et al. Treatment of Nail Psoriasis Best Practice Recommendations From the Medical Board of the National Psoriasis Foundation JAMA Dermatol. 2015;151(1):87-94.
  26.  Langenbruch A et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. British J Dermatol. 2014;171:1123-8. 
  27. Wilson FC et al. Incidence and Clinical Predictors of Psoriatic Arthritis in Patients With Psoriasis: A Population-Based Study. Arth Rheum. 2009;61(2):233-9. 
  28. Nograles KE et al. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009; 5(2): 83–91. 
  29. Doulatshahi EA et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. British J Dermatol. 2013;169:266-82.
  30. Fitzgerald O. Psoriatic arthritis. In: Firestein GS et al, eds. Kelley’s Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier Saunders; 2013:1232-50.
  31.  Nestle FO et al. Psoriasis. NEJM. 2009;361:496-509.
  32.  Lynde CW et al. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. Am Acad Dermatol http://dx.doi.org/10.1016/j.jaad.2013.12.036. 
  33. Menter A et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15. 

MX-HUMD-240002